By admin 
CureSearch for Children’s Cancer has officially announced that Dr. Robbie Majzner of the Dana-Farber Cancer Institute is the recipient of the 2026 CureSearch Catapult Award, a prestigious $2 million grant aimed at advancing a novel immunotherapy for one of the most challenging pediatric cancers. This significant investment, co-funded by the Jeff Gordon Children’s Foundation, is earmarked for a Phase I clinical trial that will evaluate a next-generation Chimeric Antigen Receptor (CAR) T-cell therapy specifically designed for children and young adults with relapsed or refractory neuroblastoma. By targeting the persistent "valley of death" between laboratory discovery and clinical application, the award seeks to provide a lifeline for patients who have exhausted standard treatment protocols.
The Critical Challenge of High-Risk Neuroblastoma
Neuroblastoma is a cancer that develops from immature nerve cells found in several areas of the body, most commonly arising in and around the adrenal glands. It remains the most common extracranial solid tumor in children, accounting for approximately 7% to 10% of all pediatric oncology cases. Despite its relatively low incidence compared to adult cancers, its impact is disproportionately severe, contributing to more than 10% of all childhood cancer deaths.
For patients diagnosed with high-risk neuroblastoma, the medical landscape is fraught with difficulty. Current standard-of-care treatments involve an intensive regimen of high-dose chemotherapy, surgical resection, radiation therapy, and autologous stem cell transplants. Even with such aggressive interventions, the five-year survival rate for high-risk cases remains stubbornly below 50%. Furthermore, those who do survive often face a lifetime of chronic health issues resulting from the toxicity of their treatments, including hearing loss, cardiac dysfunction, and secondary malignancies. When the disease relapses or becomes refractory to these treatments, the prognosis shifts from guarded to devastating, as there are currently no curative standard therapies for recurrent neuroblastoma.
Advancing Immunotherapy: The Evolution of CAR T-Cell Technology
The emergence of CAR T-cell therapy has revolutionized the treatment of hematologic malignancies, such as B-cell acute lymphoblastic leukemia (ALL) and certain types of lymphoma. This "living drug" approach involves extracting a patient’s own T-cells—the soldiers of the immune system—and genetically engineering them to express a receptor that recognizes a specific protein on the surface of cancer cells. Once infused back into the patient, these cells seek out and destroy the malignancy.
However, translating the success seen in blood cancers to solid tumors like neuroblastoma has proven to be an immense scientific hurdle. Solid tumors present a hostile microenvironment that suppresses immune activity, and they often lack uniform targets. Furthermore, CAR T-cells in solid tumors frequently succumb to "T-cell exhaustion," a state where the engineered cells become physically and functionally spent, losing their ability to proliferate and kill cancer cells shortly after entering the body.
Dr. Robbie Majzner’s research at Dana-Farber Cancer Institute focuses on overcoming these specific barriers. His team’s approach targets GD2, a disialoganglioside expressed on the surface of nearly all neuroblastoma cells. While GD2 has been targeted by monoclonal antibodies like dinutuximab in the past, previous attempts at GD2-targeted CAR T-cells have been hindered by limited persistence in the patient’s system.
The ZAP70 Innovation: Engineering for Persistence
The core innovation of the upcoming clinical trial lies in a redesigned CAR architecture. Dr. Majzner’s team has incorporated a novel signaling protein known as ZAP70 (zeta-chain-associated protein kinase 70) into the CAR T-cell construct. In a natural immune response, ZAP70 is critical for the activation of T-cells. By integrating this protein directly into the synthetic receptor, the researchers aim to modulate the signaling strength of the CAR T-cells.
Preclinical data suggests that this ZAP70-enhanced "next-generation" CAR architecture allows the cells to remain active for significantly longer periods. By resisting the metabolic and functional exhaustion that typically plagues solid tumor immunotherapies, these cells can sustain a prolonged attack against the tumor. In laboratory models, these redesigned cells demonstrated not only superior anti-tumor activity but also a potentially safer profile, reducing the risk of the severe inflammatory responses sometimes associated with traditional immunotherapy.
Dr. Majzner noted that current GD2-targeted therapies often fail in patients with significant tumor burdens, working only when the disease is minimal. The goal of this new trial is to break through those limitations, providing a robust treatment option for patients with advanced, refractory disease.
Bridging the Funding Gap: The Role of the Catapult Award
The CureSearch Catapult Award was established to address a systemic failure in the drug development pipeline known as the "Translation Gap." While academic laboratories are excellent at identifying new biological targets and developing early-stage prototypes, the cost and regulatory complexity of launching a Phase I clinical trial are often prohibitive. Federal funding is frequently insufficient for the clinical manufacturing and rigorous monitoring required for human trials, and pharmaceutical companies are often hesitant to invest in pediatric-specific therapies due to the smaller market size compared to adult oncology.
The $2 million investment from CureSearch and the Jeff Gordon Children’s Foundation provides the necessary capital to move Dr. Majzner’s work from the benchtop to the bedside. This funding covers the costs of Good Manufacturing Practice (GMP) cell production, clinical trial coordination, and the intensive monitoring of the first cohort of pediatric patients.
Dr. Paisley Myers, Senior Director of Research & Programs at CureSearch, emphasized that the Catapult Award is specifically designed to identify "bold, high-potential research." By providing the momentum needed to initiate clinical trials, the award ensures that scientific breakthroughs do not languish in academic journals but instead reach the children who are currently fighting for their lives.
Chronology of Development and Trial Roadmap
The journey to the 2026 Catapult Award began several years ago in the laboratory, where Dr. Majzner’s team first identified the signaling limitations of first- and second-generation CAR T-cells in solid tumors. Following years of iterative design and testing in preclinical mouse models, the team successfully demonstrated that the ZAP70-integrated CARs could eradicate neuroblastoma tumors that were resistant to standard CAR T-cells.
With the award funding now secured, the timeline for the Phase I trial is expected to proceed as follows:
- Trial Activation (Late 2025 – Early 2026): Finalization of the clinical protocol and approval from the Institutional Review Board (IRB) and the Food and Drug Administration (FDA) via an Investigational New Drug (IND) application.
- Patient Enrollment: Recruitment of children and young adults with relapsed or refractory neuroblastoma. This phase will focus primarily on safety and dose-finding, ensuring the therapy is tolerated by young patients.
- Data Collection and Analysis: Researchers will monitor the persistence of the CAR T-cells in the bloodstream, evaluate changes in tumor size through imaging, and analyze the immune environment within the tumors via biopsies.
- Expansion and Future Phases: If the Phase I trial meets its safety and preliminary efficacy endpoints, the research will move toward Phase II trials, which involve larger patient populations and a greater focus on overall survival rates.
Broader Implications for Pediatric Oncology
The success of this trial could have implications far beyond the treatment of neuroblastoma. GD2 is also expressed in other difficult-to-treat pediatric cancers, including osteosarcoma and certain types of brain tumors like Diffuse Midline Glioma (DMG). If the ZAP70-enhanced CAR T-cells prove effective in neuroblastoma, the same architecture could potentially be adapted to treat a variety of other solid tumors that have previously been resistant to immunotherapy.
Furthermore, this research contributes to the broader understanding of T-cell biology. By demonstrating how to prevent "exhaustion" in engineered cells, Dr. Majzner’s work may provide a blueprint for adult oncology researchers working on common solid tumors like lung, breast, and pancreatic cancer.
The partnership between CureSearch and the Jeff Gordon Children’s Foundation highlights a growing trend in the "venture philanthropy" model, where non-profit organizations act as catalysts for medical innovation. By de-risking early-stage clinical research, these organizations make it more likely that successful therapies will eventually attract the industry partnerships needed for global distribution and FDA approval.
Conclusion and Future Outlook
The 2026 CureSearch Catapult Award represents a pivotal moment for pediatric neuroblastoma research. While the road from a Phase I trial to a widely available treatment is long, the transition of Dr. Majzner’s ZAP70-enhanced CAR T-cell therapy into the clinic offers a new sense of hope. For the hundreds of families each year who receive the devastating news of a neuroblastoma relapse, this trial represents more than just a scientific experiment; it represents the potential for a future where high-risk pediatric cancer is no longer a terminal diagnosis.
As the trial commences at Dana-Farber Cancer Institute, the oncology community will be watching closely. The data generated will provide critical insights into the next generation of immunotherapy, potentially reshaping the standard of care for children and young adults across the globe. By investing in bold science and bridging the gap between discovery and care, CureSearch and its partners are actively working to change the trajectory of childhood cancer treatment.
